LLY

744.73

-1.3%↓

JNJ

177.09

-0.56%↓

ABBV

214.89

-1.56%↓

UNH

348.74

-1.18%↓

AZN

77.76

-2.24%↓

LLY

744.73

-1.3%↓

JNJ

177.09

-0.56%↓

ABBV

214.89

-1.56%↓

UNH

348.74

-1.18%↓

AZN

77.76

-2.24%↓

LLY

744.73

-1.3%↓

JNJ

177.09

-0.56%↓

ABBV

214.89

-1.56%↓

UNH

348.74

-1.18%↓

AZN

77.76

-2.24%↓

LLY

744.73

-1.3%↓

JNJ

177.09

-0.56%↓

ABBV

214.89

-1.56%↓

UNH

348.74

-1.18%↓

AZN

77.76

-2.24%↓

LLY

744.73

-1.3%↓

JNJ

177.09

-0.56%↓

ABBV

214.89

-1.56%↓

UNH

348.74

-1.18%↓

AZN

77.76

-2.24%↓

Home・Aktien・Cogent Biosciences Inc

Cogent Biosciences Inc

Open

12.54 -0.63

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

12.38

Max

12.76

Schlüsselkennzahlen
By Trading Economics
Einkommen	-1.5M -74M
Gewinnspanne	-1,582.642
Angestellte	205
EBITDA	1.7M -72M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+65.24% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	10. Nov. 2025

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	91M 1.8B
Vorheriger Eröffnungskurs	13.17
Vorheriger Schlusskurs	12.54

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

4.88 / 5.87 Unterstützung & Widerstand

Cogent Biosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Sept. 2025, 22:41 UTC

Wichtige Markttreiber

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

12. Sept. 2025, 16:04 UTC

Wichtige Markttreiber

Upexi Shares Climb on Solana Gains

14. Sept. 2025, 23:48 UTC

Market Talk

Oil Futures Mixed Amid Divergent Signals -- Market Talk

14. Sept. 2025, 23:41 UTC

Market Talk

Gold Edges Lower on Likely Technical Correction -- Market Talk

14. Sept. 2025, 23:38 UTC

Market Talk

China's Economic Activity Data May Continue Reflecting Slowdown -- Market Talk

14. Sept. 2025, 23:13 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14. Sept. 2025, 23:13 UTC

Market Talk

Global Energy Roundup: Market Talk

14. Sept. 2025, 23:13 UTC

Market Talk

Infratil May Need to Be More Aggressive With Asset Sales -- Market Talk

14. Sept. 2025, 23:13 UTC

Market Talk

Global Equities Roundup: Market Talk

14. Sept. 2025, 23:04 UTC

Market Talk

Aristocrat's Interactive Unit Appears in Safe Hands -- Market Talk

13. Sept. 2025, 08:20 UTC

Market Talk

Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

12. Sept. 2025, 20:50 UTC

Market Talk

Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

12. Sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. Sept. 2025, 20:09 UTC

Ergebnisse

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

12. Sept. 2025, 19:23 UTC

Market Talk

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12. Sept. 2025, 19:16 UTC

Market Talk

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12. Sept. 2025, 19:03 UTC

Market Talk

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

12. Sept. 2025, 18:59 UTC

Market Talk

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

12. Sept. 2025, 18:38 UTC

Market Talk

Ergebnisse

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

12. Sept. 2025, 18:33 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

12. Sept. 2025, 18:22 UTC

Market Talk

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

12. Sept. 2025, 16:56 UTC

Market Talk

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

12. Sept. 2025, 16:22 UTC

Ergebnisse

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

12. Sept. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. Sept. 2025, 16:19 UTC

Akquisitionen, Fusionen, Übernahmen

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12. Sept. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

12. Sept. 2025, 16:11 UTC

Ergebnisse

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

12. Sept. 2025, 15:37 UTC

Market Talk

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

12. Sept. 2025, 15:22 UTC

Market Talk

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

12. Sept. 2025, 15:07 UTC

Akquisitionen, Fusionen, Übernahmen

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

Peer-Vergleich

Kursveränderung

Cogent Biosciences Inc Prognose

Kursziel

By TipRanks

65.24% Vorteil

12-Monats-Prognose

Durchschnitt 20.92 USD 65.24%

Hoch 30 USD

Tief 10 USD

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cogent Biosciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

13 ratings

Buy

Halten

Sell

Basierend auf 13 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Cogent Biosciences Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

4.88 / 5.87Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.